Form 8-K - Current report:
SEC Accession No. 0001104659-24-080251
Filing Date
2024-07-16
Accepted
2024-07-16 17:23:02
Documents
14
Period of Report
2024-07-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2419633d1_8k.htm   iXBRL 8-K 40863
  Complete submission text file 0001104659-24-080251.txt   256909

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA elox-20240710.xsd EX-101.SCH 3269
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE elox-20240710_def.xml EX-101.DEF 26196
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE elox-20240710_lab.xml EX-101.LAB 35952
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elox-20240710_pre.xml EX-101.PRE 24854
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2419633d1_8k_htm.xml XML 4675
Mailing Address 480 ARSENAL WAY SUITE 130 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY SUITE 130 WATERTOWN MA 02472 781-577-5300
Eloxx Pharmaceuticals, Inc. (Filer) CIK: 0001035354 (see all company filings)

EIN.: 841368850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31326 | Film No.: 241120416
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)